| 102118-7 |
Rhabdomyolysis & Metabolic myopathy multigene panel |
- |
Bld/Tiss |
Pt |
- |
Molgen |
|
ACTIVE |
Rhabdomyolysis and Metabolic myopathy multigene panel - Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
102118-7 |
|
Molgen |
|
|
Order |
|
|
|
0 |
Rhabdo + Metab myopathy mlgn pnl Bld/T |
|
|
|
N |
|
Blood; Gene; Gene panel; Molecular genetics; Molecular pathology; MOLPATH; Multi-gene study; Multiple-gene panel test; Pan; Panel.molpath; Panl; PCR; Pnl; Point in time; Random; Rhabdo + Metab myopathy mlgn pnl; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 102119-5 |
Skeletal muscle channelopathy multigene panel |
- |
Bld/Tiss |
Pt |
- |
Molgen |
|
ACTIVE |
Skeletal muscle channelopathy multigene panel - Blood or Tissue by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MOLPATH |
|
102119-5 |
|
Molgen |
|
|
Order |
|
|
|
0 |
SMC multigene panel Bld/T |
|
|
|
N |
|
Blood; Gene; Gene panel; Molecular genetics; Molecular pathology; MOLPATH; Multi-gene study; Multiple-gene panel test; Musc; Muscl; Pan; Panel.molpath; Panl; PCR; Pnl; Point in time; Random; SMC multigene panel; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 101280-6 |
MDS v3.0 - RAI v1.18.11 - Assessment Administration |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.18.11 - Assessment Administration [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
101280-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.75 |
2.74 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 101473-7 |
Gas & electrolytes panel |
- |
BldV |
Pt |
Qn |
|
|
ACTIVE |
Gas and electrolytes panel - Venous blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101473-7 |
|
|
|
|
Order |
|
|
|
0 |
Gas + Electrolytes Pnl BldV |
|
|
|
N |
|
Bld ven; Bld venous; Blood - venous; Blood gas ven; Blood ven; Blood venus; Chemistry; Elect; Electr; Electrolyte; Gas + Electrolytes Pnl; Gases; Lytes; Lytes Pnl; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; Venous |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 101474-5 |
Adenovirus DNA & Human Metapneumovirus & Rhinovirus RNA panel |
- |
Respiratory System Specimen |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Adenovirus DNA and Human Metapneumovirus and Rhinovirus RNA panel - Respiratory specimen by NAA with probe detection |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101474-5 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
HAdV DNA + hMPV + Rhinovirus RNA pl Resp NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Adeno virus; Amplif; Amplification; Amplified; Breathing; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HAdV; HAdV DNA & hMPV & Rhinovirus RNA pl; hMPV; HRV; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Rhino virus; RHV; Ribonucleic acid; RS; SDA; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
Release 2.75: SYSTEM: There are 2 similar system's in LOINC: 1- Respiratory system 2- Respiratory specimen Due to an applied logic, the display in the System axis for 1 is Respiratory (adjective) without specification of sample, specimen, or other specific noun, while 2 is displayed fully as Respiratory specimen. Therefore for now we replaced 1 with Respiratory system specimen, which will affect 83 term. The result is replacing "Respiratory" with "Respiratory system specimen". This is the short approach. The bigger project is to potentially merge data that has either 1 or 2 together. This is a project to pass by the laboratory committee and will involve about 1500 concepts.; |
0 |
|
| 94531-1 |
SARS coronavirus 2 RNA panel |
- |
Respiratory System Specimen |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
94531-1 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
SARS-CoV-2 RNA Pnl Resp NAA+probe |
|
|
|
|
|
2019 Novel Coronavirus; 2019-nCoV; 3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Breathing; Corona virus; COVID19; COVID-19; DNA NUCLEIC ACID PROBE; DNA probe; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; Ribonucleic acid; RS; SARS Coronavirus 1; SARS-CoV; SARS-CoV-1; SARS-CoV-2; SARS-CoV-2 RNA Pnl; SDA; Severe Acute Respiratory Syndrome; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral Pneumonias; Wuhan coronavirus |
2.76 |
2.68 |
|
Panel |
81959-9 |
|
|
|
|
|
|
|
Release 2.75: SYSTEM: There are 2 similar system's in LOINC: 1- Respiratory system 2- Respiratory specimen Due to an applied logic, the display in the System axis for 1 is Respiratory (adjective) without specification of sample, specimen, or other specific noun, while 2 is displayed fully as Respiratory specimen. Therefore for now we replaced 1 with Respiratory system specimen, which will affect 83 term. The result is replacing "Respiratory" with "Respiratory system specimen". This is the short approach. The bigger project is to potentially merge data that has either 1 or 2 together. This is a project to pass by the laboratory committee and will involve about 1500 concepts.; |
0 |
|
| 94674-9 |
Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol ratio panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2/24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 ratio panel in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
94674-9 |
|
|
|
|
Order |
|
|
|
0 |
25D3+25D2/24,25D3+24,25D2 Pnl SerPl |
|
|
|
|
|
24(R),25-dihydroxycholecalciferol; 24,25(OH)2 VitD; 24,25(OH)2 VitD Pnl; 24,25-dihydroxy cholecalciferol; 24,25-dihydroxy vitamin D; 24,25-Dihydroxyvitamin D; 24,25-Dihydroxyvitamin D2 +24,25-Dihydroxyvitamin D3; 24r-Hydroxy calcidiol; 24R-OH-Calcidiol; 25 Hydroxyvitamin D 2; 25 Hydroxyvitamin D2; 25(OH)D2; 25(OH)D3; 25(OH)D3+25(OH)D2; 25D3+25D2/24,25D3+24,25D2; 25D3+25D2/24,25D3+24,25D2 Pnl; 25-Hydroxy calciferol; 25-Hydroxy Vit D total; 25-Hydroxycalciferol; 25-hydroxycholecalciferol; 25-Hydroxyergocalciferol; 25-hydroxyvitamin D; 25-Hydroxyvitamin D 2; 25-hydroxyvitamin D 3; 25-Hydroxyvitamin D2; 25-Hydroxyvitamin D2+25-Hydroxyvitamin D3/24,25 Dihydroxyvitamin D; 25-Hydroxyvitamin D2+25-Hydroxyvitamin D3/24,25 Dihydroxyvitamin D2+24,25 Dihydroxyvitamin D3; 25-Hydroxyvitamin D2+25-Hydroxyvitamin D3/24,25-Dihydroxyvitamin D ratio panel; 25-hydroxyvitamin D3; 9,10-Secoergosta-5,7,10(19),22-tetraene-3 beta,25-diol; Calciderol; Calcidiol+Calciferol; Calcidiol+Ercalcidiol; Calcifediol; Chemistry; CYP24A1 gene; Ercalcidiol; Ercalcidiol+calcidiol/24r-Hydroxycalcidiol; Ercalcidiol+calcidiol/24r-Hydroxycalcidiol Ratio Panel; Hydroxy calcidiol; Hypercalcemia; OH-Calcidiol; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Vitamin D 25 hydroxy |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 94859-6 |
Glycerol & Glycerol-corrected triglyceride panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Glycerol and glycerol-corrected triglyceride panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
94859-6 |
|
|
|
|
Order |
|
|
|
0 |
Glycerol + glycerol corr TG Pnl SerPl |
|
|
|
|
|
Chemistry; Glycerol + glycerol corr TG Pnl; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tg; Trig; Trigly; Triglycerides; Triglycrides |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 94864-6 |
Transthyretin-associated familial amyloidosis panel |
- |
Bld |
Pt |
- |
|
|
ACTIVE |
Transthyretin-associated familial amyloidosis panel - Blood |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
94864-6 |
|
|
|
|
Order |
|
|
|
0 |
TTR-assoc familial amyloidosis Pnl Bld |
|
|
|
|
|
Assoc; Blood; Chemistry; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; TTR; TTR-assoc familial amyloidosis Pnl; WB; Whole blood |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 95028-7 |
FASI v1.0 - Instrumental Activities of Daily Living |
- |
^Patient |
- |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Instrumental Activities of Daily Living [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95028-7 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95029-5 |
FASI v1.0 - Instrumental Activities of Daily Living - usual performance |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Instrumental Activities of Daily Living - usual performance during assessment period [CMS Assessment] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95029-5 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.69 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95030-3 |
FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance |
- |
^Patient |
1Mo |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95030-3 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
1 month; 1 month (30 days); 30 days; Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95031-1 |
FASI v1.0 - Assistive Devices for Everyday Activities |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Assistive Devices for Everyday Activities [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95031-1 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95032-9 |
FASI v1.0 - Functional Abilities and Goals |
- |
^Patient |
- |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Functional Abilities and Goals [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95032-9 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95033-7 |
FASI v1.0 - Preferences for Customary Routine and Activities |
- |
^Patient |
- |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Preferences for Customary Routine and Activities [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95033-7 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95034-5 |
FASI v1.0 - Availability of Assistance |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Availability of Assistance [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95034-5 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95035-2 |
FASI v1.0 - Availability of Paid and Unpaid Assistance |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Availability of Paid and Unpaid Assistance [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95035-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95036-0 |
FASI v1.0 - Availability of Paid Assistance |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Availability of Paid Assistance [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95036-0 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95037-8 |
FASI v1.0 - Availability of Unpaid Assistance |
- |
^Patient |
Pt |
- |
CMS Assessment |
|
ACTIVE |
FASI v1.0 - Availability of Unpaid Assistance [CMS Assessment] |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
95037-8 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
|
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Point in time; Random; Survey |
2.68 |
2.68 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
|
| 95140-0 |
Herpes simplex virus 1 & 2 DNA panel |
- |
Amnio fld |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 1 and 2 DNA panel - Amniotic fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
95140-0 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
HSV 1+2 DNA Pnl Amn NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; AF; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type 1+2; Herpes simplex virus type I+II; HSV; HSV 1+2; HSV 1+2 DNA Pnl; HSV1; HSV1+2; i; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 95142-6 |
Hepatitis A virus Ab.IgM panel |
- |
Ser |
Pt |
- |
|
|
ACTIVE |
Hepatitis A virus IgM panel - Serum |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
95142-6 |
|
|
|
|
Order |
|
|
|
0 |
HAV IgM Pnl Ser |
|
|
|
|
|
HAV; HAV IgM Pnl; Hep; Hep A; Hepatis; Hepatit; Hepatitis; Hepatitis type A; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Serum; SR |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 95144-2 |
Hepatitis D virus RNA panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Hepatitis D virus RNA panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
95144-2 |
|
|
|
|
Order |
|
|
|
0 |
HDV RNA Pnl SerPl |
|
|
|
|
|
Delta hepatitis; Dextro; HDV; HDV RNA Pnl; Hep; Hep D; Hep Delta; Hepatis; Hepatit; Hepatitis delta virus; Hepatology; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; Ribonucleic acid; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 95145-9 |
Hepatitis B virus core Ab panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Hepatitis B virus core Ab panel - Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
95145-9 |
|
|
|
|
Order |
|
|
|
0 |
HBV core Ab Pnl SerPl |
|
|
|
|
|
anti-HBc; HBc; HBV; HBV core; HBV core Ab Pnl; Hep; Hep B; Hepatis; Hepatit; Hepatitis Bc; Hepatology; HepB; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
| 95356-2 |
Pretransplant assessment of mortality score panel |
- |
^Patient |
Pt |
- |
PAM.Revised |
|
ACTIVE |
Revised Pretransplant Assessment of Mortality (PAM) Score panel |
|
PANEL |
DefinitionDescription |
|
|
|
|
�©2015 Fred Hutchinson Cancer Research Center. Used with permission. |
|
|
|
|
PANEL.CLIN.RISK |
|
95356-2 |
|
PAM.Revised |
|
|
Observation |
|
|
|
0 |
Revised PAM Score Pnl |
|
|
|
|
|
CLIN; CLIN.RISK; PAM Score; PAM Score Pnl; Pan; PANEL.CLINICAL; Panl; Pnl; Point in time; Random |
2.69 |
2.68 |
|
Panel |
|
|
�©2015 Fred Hutchinson Cancer Research Center. Used with permission. |
|
|
|
|
|
|
0 |
|
| 95358-8 |
Rabbit hemorrhagic disease virus RNA panel |
- |
XXX |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Rabbit hemorrhagic disease virus RNA panel - Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
95358-8 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
RHDV RNA Pnl Spec NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Calicivirus; Dis; Diseases; DNA NUCLEIC ACID PROBE; DNA probe; Dz; f213; Hemorrhagic septicemia; Infectious necrotic hepatitis; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Oryctalagus spp; Other; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Rabbit hemorrhagic disease; Random; RHDV; RHDV RNA Pnl; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Vet; Veterinary; Viral hemorrhagic disease |
2.69 |
2.68 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
|
